iNtRON, Development of PHAGERIA® Anti-Cancer Candidate with Enhanced Antimicrobial Activity by Robot Bacteriophage platform technology
Intron Biotechnology said Monday that it has secured a new drug substance, SPL200, based on endolysin with excellent antibacterial activity against pneumococcus, the primary cause of bacterial pneumonia.
Roivant joins forces with Korea’s iNtRON Bio to fight superbugs